Publicaciones en las que colabora con JOSE VICENTE CASTELL RIPOLL (75)

2024

  1. Assessing ATR-FTIR spectroscopy for steatosis quantification in liver biopsies in a long-duration cross-sectional study

    Microchemical Journal, Vol. 198

  2. Cluster-Partial Least Squares (c-PLS) regression analysis: Application to miRNA and metabolomic data

    Analytica chimica acta, Vol. 1286, pp. 342052

  3. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways

    International Journal of Molecular Sciences, Vol. 25, Núm. 10

  4. Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis

    International Journal of Molecular Sciences, Vol. 25, Núm. 5

2023

  1. Enhancing the accuracy of mid-infrared spectroscopy-based liver steatosis quantification using digital image analysis as a reference

    Analyst, Vol. 148, Núm. 13, pp. 3097-3106

  2. Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients

    Nutrients, Vol. 15, Núm. 14

2022

  1. Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen

    Antioxidants, Vol. 11, Núm. 5

  2. Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat

    International journal of molecular sciences, Vol. 23, Núm. 16

2021

  1. Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways

    Food and Chemical Toxicology, Vol. 158

  2. Safer chemicals using less animals: kick-off of the European ONTOX project

    Toxicology, Vol. 458

2020

  1. A novel MicroRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients

    Toxicological Sciences, Vol. 173, Núm. 2, pp. 229-243

  2. Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes

    Archives of Toxicology, Vol. 94, Núm. 2, pp. 589-607

  3. The vitamin D receptor regulates glycerolipid and phospholipid metabolism in human hepatocytes

    Biomolecules, Vol. 10, Núm. 3

  4. Toward Rapid Screening of Liver Grafts at the Operating Room Using Mid-infrared Spectroscopy

    Analytical Chemistry, Vol. 92, Núm. 21, pp. 14542-14549

2019

  1. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease

    Molecular Nutrition and Food Research, Vol. 63, Núm. 20

2018

  1. Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems

    Food and Chemical Toxicology, Vol. 120, pp. 196-212

  2. Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis

    American Journal of Pathology, Vol. 188, Núm. 12, pp. 2800-2810

  3. Non-invasive prediction of NAFLD severity: A comprehensive, independent validation of previously postulated serum microRNA biomarkers

    Scientific Reports, Vol. 8, Núm. 1

  4. Predicting drug-induced cholestasis: preclinical models

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 14, Núm. 7, pp. 721-738

2017

  1. New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease

    Frontiers in Pharmacology, Vol. 8, Núm. JAN